Ignyta, Inc. RXDX today announced that interim results from the
company's ongoing Phase 1 clinical trial of RXDX-105, the company's
orally-available, small molecule multikinase inhibitor with potent
activity against such key targets as RET and BRAF, were presented at the
27th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer
Therapeutics in Boston, Massachusetts.
"We are excited by the data from our Phase 1 clinical trial of RXDX-105,
including the overall safety profile and the recent partial response in
a non-small lung cancer patient," said Pratik Multani, M.D., Chief
Medical Officer of Ignyta. "We believe we are close to determining the
recommended phase 2 dose (RP2D) and we look forward to further
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in